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A B S T R A C T
Background: Neuromodulation is nowadays investigated as a promising method for pain relief. Research in-
dicates that a single 30-minute stimulation with transcranial pulsed electromagnetic ﬁelds (tPEMF) can induce
analgesic eﬀects. However, it is unknown whether tPEMF can induce analgesia in neuropathic pain patients.
Objective: To evaluate the eﬀect of tPEMF on spontaneous pain and heat pain in neuropathic pain patients.
Methods: This study had a randomized double-blind crossover design. Twenty neuropathic pain patients re-
ceived 30-minutes of tPEMF and 30-minutes sham stimulation. Primary outcomes were pain intensity, pain
aversion and heat pain. Secondary outcomes included aﬀect, cognition, and motor function, to investigate safety,
tolerability and putative working mechanisms of tPEMF. Outcomes were assessed before, during and after sti-
mulation.
Results: No diﬀerences in analgesic eﬀects between tPEMF and sham stimulation were found for pain intensity,
pain aversion or heat pain. No diﬀerences between tPEMF and sham stimulation were observed for aﬀect, motor,
and cognitive outcomes.
Conclusion: A single 30-minute tPEMF stimulation did not induce analgesic eﬀects in neuropathic pain patients,
compared to sham. Further study is needed to determine whether prolonged stimulation is necessary for an-
algesic eﬀects.
1. Introduction
Transcranial pulsed electromagnetic ﬁeld stimulation (tPEMF) has
been reported to show promising results in pain reduction, even after a
single 30min trial [1–4]. If proven eﬀective, this form of neuromodu-
lation may have clinical beneﬁts, e.g. it may be applicable at home. It is
currently unknown whether tPEMF would have an analgesic eﬀect in
patients with neuropathic pain.
Neuropathic pain is an impairing and often chronic pain disorder
caused by a lesion or disease of the somatosensory nervous system [5].
Neuropathic pain-inducing nerve damage can have diverse etiologies,
such as injuries, diabetes, multiple scleroses, and tumors. Damage to
peripheral or central pain pathway neurons causes them to ﬁre in-
appropriately. This leads to perceived pain and abnormal responses to
noxious and innocuous stimuli that are experienced as burning, elec-
trical, throbbing, or stabbing sensations. Traditional treatment of neu-
ropathic pain includes pharmacological, psychological, surgical, and
physical approaches [6]. However, these treatments are marked by low
eﬀectiveness, and considerable risks and side eﬀects [7–11]. This marks
a distinctive need for alternative treatment methods such as tPEMF.
tPEMF consists of speciﬁc magnetic waves of a low intensity, in the
order of milli- or microteslas, which are applied transcranially in a
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pulsating fashion. The use of several small electromagnets allows for
both focally targeted and extended cerebral stimulation. Several animal
experiments found analgesic properties of tPEMF [12–14]. This was
extended to healthy human volunteers, where researchers, including
our own group, also observed a decreased level of subjective pain in
response to thermal stimulation after 30min of tPEMF [1,4].
The ﬁrst double-blind placebo-controlled randomized trials for pain
patients have been published in ﬁbromyalgia. A single 30-minute
tPEMF stimulation induced reductions in pain ratings in ﬁbromyalgia
and rheumatoid arthritis patients [3]. A setup using a longer treatment
period (seven days) seemed to elicit an analgesic eﬀect in chronic ﬁ-
bromyalgia patients with generalized pain (trend eﬀect of p= .06), but
not in patients with chronic localized musculoskeletal or inﬂammatory
pain [15]. In addition, reductions in self-reported chronic pain scores
were found in ﬁbromyalgia patients who received magnetic stimulation
once a week for 20min, for eight weeks [16]. No signiﬁcant side eﬀects
have been reported after prolonged tPEMF.
The mechanism by which tPEMF can induce analgesia is unknown.
Besides the possibility of an opioid-mediated eﬀect on pain perception
[14], evidence suggests that analgesic eﬀects might occur by inﬂuen-
cing the aﬀective component of pain (i.e. the unpleasantness or aver-
sion), rather than sensory aspects or pain intensity. This was suggested
after observing tPEMF induced neuromodulation in the insula, anterior
cingulate, and hippocampus/caudate [17]. These areas are typically
associated with the aﬀective components in pain perception [18].
Further, Martiny et al. [19] found prolonged stimulation with tPEMF
(30min, for 25 days) to have antidepressant eﬀects. Recent ﬁndings
also emphasize a role of dopamine. Dopamine inﬂuences the aﬀective
aspects of pain [20], and dopamine regulation is often disturbed in
chronic pain patients [21]. Dopaminergic tone has also been found to
be sensitive to magnetic stimulation [22,23]. The eﬀect of tPEMF on the
aﬀective experience of pain might therefore be an important factor for
analgesia.
The current study investigated the analgesic qualities of tPEMF in
neuropathic pain patients on both spontaneous pain and heat pain. It
was hypothesized that 30min of tPEMF would reduce perceived pain
and increase heat pain tolerance. To explore safety, tolerability and
possible mechanisms by which tPEMF might induce analgesia, mea-
sures of aﬀect, cognitive performance, and dopaminergic correlates
were assessed.
2. Material and methods
2.1. Participants
Twenty neuropathic pain inpatients were recruited at the University
Medical Center Groningen (see Supplement 1). Inclusion criteria were
age 18–80, being subjectively healthy (with exception of the neuro-
pathic pain), and having a neuropathic pain diagnosis with a “prob-
able’’ or “deﬁnite’’ Treede Grade (indicating that the presence of the
condition has been established by neurological examination) [24]. Ex-
clusion criteria were pregnancy, epilepsy, epilepsy in a ﬁrst degree
relative, use of antiepileptic, prescription or non-prescription psy-
choactive drugs within the last four weeks (except for pain medication),
excessive coﬀee or alcohol use (> 10 units per day), MRI incompatible
implants, manifest signs/symptoms of neurological deﬁcits or a psy-
chiatric disorder, and a history of head trauma with consciousness loss
(duration> 5min).
2.2. Design and procedure
This study had a randomized double-blind crossover design.
Participants were tested twice; once they received tPEMF and once
sham stimulation. Test moments took place at the same time of the day,
with seven days in between. A measurement session was divided into
four blocks (see Fig. 1). Participants were familiarized with the testing
regime prior to the ﬁrst block by practicing all tasks once. Next, ques-
tionnaires on aﬀective state were administered and the tPEMF cap was
ﬁtted, then the ﬁrst block started. During the four consecutive ﬁfteen-
minute blocks, tasks were administered repeatedly. The ﬁrst block was
the baseline measurement, during which no stimulation was given.
During the second and third block participants received either tPEMF or
sham stimulation. No stimulation was given during the fourth block.
Within the tPEMF condition, participants received 30min tPEMF
with either high (n=10) or low (n=10) stimulation intensity to
monitor for dose-response relationships. Stimulation order and stimu-
lation intensity (high, low) were randomized in a balanced manner.
Participants and assessors were blind for stimulation order and in-
tensity. The treatments were administered by running small executable
ﬁles on a PC of identical size and time stamp, and could not be dif-
ferentiated. Unblinding took place after completion of both sessions.
2.3. tPEMF
tPEMF was applied with a device designed by our research group.
Electromagnetic ﬁelds were evoked by nineteen small electromagnets
which were attached radially on a regular EEG cap according to the
international 10/20 system (see Supplement 2). The magnetic ﬁeld
pattern was based on the” complex neural pulse” which was developed
to target pain [25]. High intensity stimulation existed of a pulse pattern
ranging from -2.75m T to +2.30m T. For low intensity stimulation the
pulse intensity ranged from -1.27m T to +1.15m T. During sham sti-
mulation a zero amplitude magnetic ﬁeld was delivered. Further details
on the device and pulse pattern are described in Kortekaas et al. [4].
Magnetic ﬁeld strengths were checked with the FH 54 magnetic ﬁeld
strength meter (Magnetic-Physik, Cologne, Germany).
2.4. Primary outcomes
2.4.1. Pain scores
Participants indicated the pain intensity (minute 14 of each block)
of the neuropathic pain on a numerical rating scale (NRS) ranging from
0 ‘no pain at all’ to 10 ‘most intense pain imaginable’. Pain aversion was
rated on a NRS ranging from 0 ‘not bothering at all’ to 10 ‘worst pain
imaginable’.
2.4.2. Warmth detection thresholds (WDT) and heat pain (HP)
WDT and HP were determined twice per ﬁfteen-minute block
(minute 1 and 8) using a thermode with a 3 x 3 cm surface area
(Pathway-ATS, Medoc, Ramat Yishai, Israel). The thermode was at-
tached to the patient’s non-dominant normosensitive hand. The ther-
mode heated up from 32 °C at 0.3 °C/s to maximally 50 °C, and cooled
down by 3 °C/s. WDT refers to the temperature at which participants
verbally indicated that they were certain that the thermode had started
to heat up. HP refers to the temperature at which participants described
the intensity of heat-induced pain with a 7 on a scale ranging from 0 ‘no
pain at all’ to 10 ‘most intense pain imaginable’. WDT and HP were
recorded in triple, the median was used for analysis.
2.5. Secondary outcomes
2.5.1. Aﬀective state
The Proﬁle of Mood States (POMS) [26] and the Positive And Ne-
gative Aﬀect Schedule (PANAS) [27] were completed before and after
each session.
2.5.2. Motor outcomes
The motor variables ﬁnger tapping speed and handwriting size were
assessed as these are dopaminergic correlates [28,29]. Finger tapping
speed was measured twice per block in duplo (minute 4 and 11). Par-
ticipants pressed a hand counter with the thumb of their dominant hand
as often as possible for 20 s. Handwriting size was assessed once per
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block (minute 6) by copying a sentence (24 words, 132 characters). The
surface of the written text was determined in cm2.
2.5.3. Neurocognitive functioning
The Digit-to-Symbol Substitution Test (DSST) [30] was completed
once per block (minute 13).
2.5.4. Exit interview
After each session an exit interview took place on side eﬀects and
blinding.
2.6. Analysis
Data were analyzed with IBM SPSS Statistics 22. The two stimula-
tion intensity groups were compared at baseline on age (t-test) and
gender (chi-square test), signiﬁcance was accepted at p= .05.
First, primary outcomes and aﬀect variables were analyzed with
paired-samples t-tests (two-sided) on diﬀerence scores between pre and
post-measurements to establish whether people beneﬁted from tPEMF.
The pre-score was deﬁned as the measurement closest to the start of the
stimulation. The ﬁrst measurement after the stimulation ended was
used as the post-measurement. Signiﬁcance was accepted at p= .05.
Second, primary and secondary outcomes were analyzed with three-
way repeated measures ANOVAs (RM-ANOVA) on treatment (sham,
tPEMF), stimulation intensity (high, low) and time (time of measure-
ment in minutes). Because including the factor stimulation intensity
reduces the power, the data were also analyzed with two-way RM-
ANOVA on treatment (sham, tPEMF) and time (time of measurement in
minutes). The Greenhouse-Geisser correction was applied if the data
were non-spherical. Signiﬁcance was accepted at p= .05 for primary
outcomes, and for secondary outcomes at p=.005 (Bonferroni corrected
for 10 tests). The assumption of normality was not met for the diﬀer-
ence scores of HP and the subscales of the POMS and PANAS, therefore
nonparametric Wilcoxon Signed Ranks tests were performed.
This research was largely exploratory and no literature was avail-
able to permit a reliable sample size calculation. Therefore sample size
was based on risk estimates and similar types of studies in literature
[1,3,4,15].
2.7. Ethics
The trial was approved by the Medical Ethical Committee of the
University Medical Center Groningen. Participants signed informed
consent and received no ﬁnancial compensation. The trial was regis-
tered in the Dutch Trial Register (NTR1093).
3. Results
Twenty participants with a mean age of 54.8 (SD=14.5) were in-
cluded, eleven were male. See supplement 3 for clinical characteristics.
Ten participants had deﬁnite neuropathic pain, and ten probable ac-
cording to the Treede Grade. Two patients had an interval of two weeks
between measurements instead of one week. None of the patients
dropped out. No adverse eﬀects were reported. No relation was found
between stimulation order and guess of order (60% was guessed cor-
rectly), indicating that blinding was achieved. The low and high in-
tensity stimulation groups diﬀered signiﬁcantly on gender (low=90%
male, high=20% male, p < .01).
3.1. Stimulation intensity
No signiﬁcant main or interaction eﬀect of stimulation intensity was
found. Therefore, only results of the two-way RM-ANOVA - in which
the factor intensity was not included - are presented.
3.2. Primary outcomes
No signiﬁcant diﬀerence was found in change scores of pain in-
tensity (t(19)= 0.01, p= .91) or pain aversion between sham and
tPEMF (t(19)=-.053, p= .61). The RM-ANOVA did show a decreasing
trend (Fig. 2) of pain intensity over time (F(357)= 2.39, p= .08),
however no eﬀect of treatment or an interaction eﬀect for time x
treatment (F(357)= 0.43, p= .73) was found. A downward trend over
time was also found for pain aversion (F(357)= 2.39, p= .08), but no
Fig. 1. Overview of the stimulation and measurement protocol.
Fig. 2. The average neuropathic pain intensity (a) and aversion (b) during the experiment for sham and tPEMF sessions. Error bars indicate 95% conﬁdence
intervals.
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eﬀect of treatment or an interaction eﬀect for treatment x time (F
(357)= 0.43, p= .73) was observed. The changes in pain scores per
patient can be found in Supplement 4.
Paired-samples t-tests revealed no diﬀerence in change scores of the
WDT (t(19)=-0.70, p= .50) or HP (t(19)=-0.10, p= .92) between
sham and tPEMF. RM-ANOVA showed that the HP (F(756)= 10.12,
p < .000) increased signiﬁcantly during the 60-minute trial, see Fig. 3.
No main eﬀect of treatment was found for HP nor an interaction eﬀect
for time x treatment (F(475)= 0.56, p= .69). Nonparametric testing
on HP diﬀerence scores conﬁrmed the absence of a treatment eﬀect.
WDT increased signiﬁcantly over time (F(362)= 11.82, p < .000), but
no main eﬀect of treatment was found nor an interaction eﬀect for time
x treatment (F(7133)= 1.03, p= .42).
3.3. Secondary outcomes
No signiﬁcant treatment eﬀects were present for positive aﬀect,
negative aﬀect or any dimension of the POMS, see Supplement 5. Motor
outcomes and the DSST were analyzed with RM-ANOVA; no eﬀect of
treatment or the interaction treatment x time was revealed.
4. Discussion
Our data show that short-duration tPEMF compared to sham does
not result in reductions in spontaneous pain or heat pain in neuropathic
pain patients. There was a trend reduction of spontaneous neuropathic
pain over time during both tPEMF and sham, which indicates the
possible presence of a placebo eﬀect. No eﬀect of treatment was ob-
served for warmth thresholds, cognition, aﬀect or motor variables.
Contrary to the expectations based on a study of Shupak et al. [3] in
ﬁbromyalgia and rheumatoid arthritis patients, the present neuropathic
pain patient group did not beneﬁt from 30-minute tPEMF using an al-
most identical stimulation wave. Similarly, Thomas et al. [15] could not
completely replicate the initial results of Shupak et al. [3] in ﬁ-
bromyalgia patients. In the study by Thomas et al. [15] ﬁbromyalgia
patients received 40-minutes tPEMF, twice a day, for seven days.
During these days a downward trend was seen in pain severity, in-
dicating that the treatment duration may be an important factor. Pos-
sibly our single stimulation of 30min was not long enough.
Another possible explanation for the lack of eﬀect may be that the
presumed therapeutic eﬀect of tPEMF is not applicable for neuropathic
pain. Interestingly, Thomas et al. [15] reported positive results for ﬁ-
bromyalgia patients, but no analgesic eﬀects were found when ana-
lyzing the complete sample of mixed chronic pain patients. Similar to
their group, the present patient sample was heterogeneous. Although all
patients were diagnosed with neuropathic pain, etiologies varied con-
siderably among patients. Possibly tPEMF is eﬀective for some pain
conditions, but not others. One salient similarity between our patients
was a long duration of illness and a high level of therapy resistance,
factors that in itself limit the likelihood of ﬁnding a therapeutic eﬀect. It
is known that the anatomy and somatosensory system of long-term
(neuropathic) pain patients is diﬀerent from that of healthy people and
that this includes changes in cortical thickness [31,32]. Possibly this
causes a diﬀerent or diminished eﬀect of tPEMF in neuropathic pain
patients. Another factor of interest is that patients were engaged in
cognitive tests while receiving the stimulation, as the eﬀects of neuro-
modulation have been found to be diﬀerent when applied during
resting state or performance [33]. Finally, of the participants 85% used
medication. It was previously found that anticonvulsants or anti-
depressants can lower cortical excitability [36,37]. Explorative post-
hoc t-tests on change-scores showed no limitative eﬀect of antic-
onvulsants and/or antidepressants; actually, (non-signiﬁcant) larger
reductions in average pain intensity and aversion in the tPEMF condi-
tion were found in patients who used anticonvulsants/antidepressants.
No eﬀect was observed of tPEMF on warmth detection thresholds,
indicating that sensory perception was not aﬀected. Patients did seem
to experience –expected– desensitization of the skin to innocuous
(warmth) and nociceptive (heat) thermal stimuli. Warmth detection
and heat pain of the skin showed a strong time dependence, which has
also been shown in healthy volunteers [4]. No adverse events or side
eﬀects were reported, which underscores the safety of this intervention.
The lack of eﬀect on cognitive, motor or aﬀect variables implies that the
treatment did not negatively inﬂuence neuropsychological functions or
the sensory system.
5. Limitations
There were several limitations. First, patients varied strongly in
pain; four patients scored zero at pain aversion, indicating that pain was
not evidently present. Second, ten patients did not have a deﬁnite
neuropathic pain diagnosis, but a probable as measured with the Treede
Grade. Third, 45% was female. Generally, more pronounced eﬀects of
tPEMF have been observed in females [1]. Fourth, this was a small
exploratory study, with limited statistical power. Finally, no neuro-
physiological measurements such as fMRI, EEG or fNIRS were used.
There still may have been eﬀects of tPEMF on brain activity level, as
changes on brain level have been found to occur prior to behavioral
changes [34].
6. Conclusion
With this trial we made a ﬁrst attempt at treating neuropathic pain
patients with tPEMF. In conclusion, a single 30-minute stimulation with
the pattern of tPEMF used in this study is not eﬀective in reducing
neuropathic or nociceptive pain in severe neuropathic pain patients.
The treatment was well tolerated by the patients and gave no adverse
Fig. 3. Course of WDT and HP. The WDT is presented by the lower values, and the HP by the upper values. Error bars indicate 95% conﬁdence intervals.
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events or side eﬀects. The inﬂuence of the duration and number of
stimulations may deserve future attention in the investigation of an-
algesic eﬀects of neuromodulation in chronic pain conditions.
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